

PROVIDER Update



CONTRACTUAL | APRIL 11, 2025 | UPDATE 25-336 | 7 PAGES

1st Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after June 16, 2025

The Health Net* Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective June 16, 2025 are listed on pages 2-7 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* *Provider Participation Agreement (PPA)*.

The update includes:

- 16 new injectable medications to be added to the DOFR crosswalk
- 40 updates and changes to current injectable medication procedure codes
- 15 new biosimilars to be added to the DOFR Crosswalk
- 7 updates for new generic drugs
- 1 category update

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on Health Net's provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Health Net Employer Group

HMO, POS & PPO – 800-641-7761

Medi-Cal (including CS and ECM providers)

– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc. and Health Net Community Solutions, Inc. are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Alhemo®	Concizumab-mtci SC injection	Self-injectable	
J1552	Alyglo™	Immune globulin (human)-stwk IV solution 10 GM/100 mL	Therapeutic injection	
J9999	Bizengri®	Zenocutuzumab-zbco injection, for intravenous use	Therapeutic injection	Chemotherapy ¹
J9999	Datroway®	Datopotamab deruxtecan-dlnk, IV	Therapeutic injection	Chemotherapy ¹
J2428	Erzofrii®	Injection, paliperidone palmitate extended release, 1 mg	Therapeutic injection	
J0666	Exparel®	Injection, bupivacaine liposome, 1 mg	Therapeutic injection	
90661	Flucelvax® pf	Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, antibiotic free, 0.5 ML dosage, for intramuscular use	Therapeutic injection	Immunization
90673	Flublok®	Influenza virus vaccine recombinant HA PF solution prefilled syringe 0.5 mL 2024-25	Therapeutic injection	Immunization
90662	Fluzone® high dose	Influenza virus vaccine split high-dose PF suspension	Therapeutic injection	Immunization
90656	Fluzone® 2024-2025	Influenza virus vaccine split PF suspension	Therapeutic injection	Immunization
90657	Fluzone® 2024-2025	Influenza virus vaccine split IM suspension 6-35 months, IM, 0.25 ML	Therapeutic injection	Immunization
90658	Fluzone® 2024-2025	Influenza virus vaccine split intramuscular (IM) suspension age 3 years old & over IM, 0.5 ML	Therapeutic injection	Immunization
J3590	Kebilidi™	Eladocagene exuparvovec-tneq intraputaminial infusion	Therapeutic injection	
J9999	Opdivo qvantig™	Nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use	Therapeutic injection	Chemotherapy ¹
J3490	Tryngolza™	Olezarsen sod subcutaneous solution auto-inject 8	Self-injectable	
J9999	Ziihera®	Zanidatamab-hrii injection IV Solution	Therapeutic injection	Chemotherapy ¹

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Updates/changes to injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
Q5145	Abrilada™	Injection, adalimumab-afzb , biosimilar, 10 mg 0069-0347-02; 40 mg 0069-0319-01.	Replaces Q5132
J0281	Amicar®	Aminocaproic acid	Replaces S0017
J9028	Anktiva®	Nogapendekin alfa inbakicept-pmln solution, for intravesical use	Replaces J9999
J2865	Bactrim®	Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg	Replaces S0039
J1412	Balfaxar®	Injection, prothrombin complex concentrate (human), per international units of factor IX activity	Corrects J1412
J1414	Beqvez™	Fidanacogene elaparovvec-dzkt injection, for intravenous infusion	Replaces J3590
J3392	Casgevy™	Exagamglogene autotemcel, suspension for intravenous infusion	Replaces J3590
J1890	Cephalothin sodium	Cephalothin sodium injection	No longer manufactured
J9070	Cyclophosphamide	Cyclophosphamide 100 mg injection	Code deleted
J9080	Cyclophosphamide	Cyclophosphamide 200 mg injection	Code deleted
J9090	Cyclophosphamide	Cyclophosphamide 500 mg injection	Code deleted
J9091	Cyclophosphamide	Cyclophosphamide 1.0 gram injection	Code deleted
J9092	Cyclophosphamide	Cyclophosphamide 2.0 gram injection	Code deleted
C9087	Cyclophosphamide	Injection, cyclophosphamide, (AuroMedics), 10 mg	Code deleted
J9074	Cyclophosphamide	Injection, cyclophosphamide (Sandoz), 5 mg	Updated code
J9075	Cyclophosphamide	Injection, cyclophosphamide, 5 mg, not otherwise specified	Updated code

Updates/changes to injectable medication procedure codes or HCPCS codes, continued

HCPCS	Drug name	Generic name	Comment
J9071	Cyclophosphamide	Injection, cyclophosphamide, (Auromedics), 5 mg	Updated code
J9072	Cyclophosphamide	Injection, cyclophosphamide, (Avyxa), 5 mg	Updated code
J9073	Cyclophosphamide	Injection, cyclophosphamide (Ingenus), 5 mg	Updated code
J9074	Cyclophosphamide	Injection, cyclophosphamide (Sandoz), 5 mg	Updated code
J9075	Cyclophosphamide	Injection, cyclophosphamide, not otherwise specified, 5mg	Updated code
J9076	Cyclophosphamide	Injection, cyclophosphamide (Baxter), 5 mg	Updated code
Q5143	Cytelzo®	Adalimumab-adbm; low-concentration interchangeable	Replaces C9399
J1810	Droperidol/fentanyl citrate	Droperidol/fentanyl injection	No longer manufactured
J1938	Furosemide	Furosemide injection	Replaces J1940
Q5149	Enzeevu™	Aflibercept-abzv	Replaces J3490
Q5144	Idacio®	Adalimumab-aacf	Replaces Q5131
J9026	Imdelltra™	Tarlatamab-dlle for injection, for intravenous use	Replaces J3590
J9161	Lymphir™	Denileukin diftitox-cxdl	Replaces J9999
J9038	Niktimvo™	Axatilimab-csfr	Replaces J3590
J2290	Nafcillin	Injection, nafcillin sodium, 20 mg	Replaces S0032
J2802	Nplate®	Romiplostim, 10 micrograms	Replaces J2796
J2351	Ocrevus zunovo™	Ocrelizumab hyaluronidase-ocsq	Replaces J3590
Q5147	Pavblu™	Aflibercept-ayyh intravitreal injection 2 mg/0.05 ml	Replaces J3590
J1308	Pepcid®	Famotidine, 20 mg	Replaces S0028
J1307	Piasky®	Crovalimab-akkz injection, for intravenous or subcutaneous	Replaces J3590

Updates/changes to injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
J0870	Rytelo™	Injection, imetelstat, 1 mg	Replaces J9999
J1299	Soliris®	Injection, eculizumab, 10 mg	Replaces J1300
Q2057	Tecelra®	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	Replaces J9999
J9024	Tecentriq hybreza™	Atezolizumab hyaluronidase-tqjs injection 1875-30000 mg-unit/15ml	Replaces J9999

New biosimilars to be added to the DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q5150	Ahzantive®	Injection, aflibercept-mrbb, biosimilar to Eylea 1 mg	Therapeutic injection	
J3590	Avtozma®	Tocilizumab-anoh, subcutaneous, biosimilar Actemra	Self-injectable	
J3590	Avtozma®	Tocilizumab-anoh, IV, biosimilar to Actemra	Therapeutic injection	
Q5152	Bkemv™	Injection, eculizumab-aeeb, biosimilar to Soliris, 2 mg	Therapeutic injection	Home health/ Infusion ²
Q5149	Enzeevu™	Injection, aflibercept-abzv, biosimilar to Eylea, 1 mg	Therapeutic injection	
Q5151	Epysqli®	Injection, eculizumab-aa, biosimilar, 2 mg	Therapeutic injection	Home health/ Infusion ²
Q5146	Hercessi®	Injection, trastuzumab-strf, biosimilar to Herceptin, 10 mg	Therapeutic injection	Chemotherapy ¹
Q5140	Hulio®	Injection, adalimumab-fkjp, biosimilar to Humira, 1 mg	Self-injectable	
Q5148	Nypozi®	Filgrastim-txid solution, biosimilar to Neupogen	Self-injectable	Chemotherapy adjunctive ¹

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.

New biosimilars to be added to the DOFR crosswalk, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q9999	Otulf [™]	Injection, ustekinumab-aaaz, biosimilar to Stelara, 1 mg	Self-injectable	
Q9996	Pyzchiva [®]	Injection, ustekinumab-ttwe, subcutaneous, 1 mg biosimilar to Stelara	Self-injectable	
Q9997	Pyzchiva [®]	Injection, ustekinumab-ttwe, IV, 1 mg biosimilar to Stelara	Therapeutic injection	
Q9998	Selarsdi [™]	Injection, ustekinumab-aekn, 1 mg, biosimilar to Stelara	Self-injectable	
J3590	Steqeyma [®]	Injection, ustekinumab-STBA, biosimilar to Stelara, 1 mg	Self-injectable	
Q5150	Ahzantive [®]	Injection, aflibercept-mrbb, biosimilar to Eylea 1 mg	Therapeutic injection	

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9292	Axtle [™]	Injection, pemetrexed (Axyxa), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy adjunctive ¹
J9054	Boruzu [™]	Injection, bortezomib, 0.1 mg	Therapeutic injection	Chemotherapy adjunctive ¹
J1271	Doxy 100	Doxycycline hyclate, 1mg	Therapeutic injection	
J1808	Folic acid	Injection, folic acid, 0.1 mg	Therapeutic injection	
J2804	Rifampin	Injection, rifampin, 1 mg	Therapeutic injection	
J1072	Testosterone cypionate	Injection, testosterone cypionate 1mg (Azmiro)	Therapeutic injection	Transgender hormones
J2601	Vasopressin	Injection, vasopressin (Baxter), 1 unit	Therapeutic injection	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Category changes

The following medications has been approved to correct the primary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9218	Eligard®	Leuprolide acetate) for injectable suspension, for subcutaneous use	Therapeutic injection	Chemotherapy adjunctive ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.